Stocks
Candel Therapeutics, Inc.CADL
NASDAQHealthcareBiotechnology$8.21
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for solid tumors, with lead candidates targeting prostate cancer and non-small cell lung cancer. Investors track CADL for its proprietary enLIGHTEN discovery platform and upcoming Phase 3 data readouts in localized prostate cancer.
52W Range: $4.35-$14.00
Congressional Interest in Candel Therapeutics, Inc. (CADL)
No congressional trades have been disclosed for Candel Therapeutics, Inc. (CADL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CADL?
No congressional trades found for this stock.